CORE ONE LABS INC - CLABF STOCK NEWS

Core One Labs is positioning itself to capitalize on the growing psilocybin market with its proprietary drug delivery technology. The company aims to produce pharmaceutical-grade psilocybin at significantly lower costs, leveraging a thin film oral strip for rapid absorption. Core One also operates medical clinics with a database of over 275,000 patients, integrating research and development for psychedelic treatments. Recent regulatory changes, including the decriminalization of psilocybin in D.C., present growth opportunities. Core One's strategic hires indicate readiness to pursue market share in this expanding sector.

Core One Labs Inc. (OTC PINK:CLABF) announced the expansion of its subsidiary Vocan Biotechnologies' product commercialization team with the addition of Dr. Elizabeth Matthews as Head of Scientific and Regulatory Affairs. Dr. Matthews, a microbiologist with over 18 years of experience in vaccine development, will guide the R&D and regulatory processes for Vocan’s new medicinal products. This strategic hiring aims to accelerate product commercialization and navigate regulatory landscapes more effectively, bolstering Core One’s commitment to bringing psychedelic medicines to market.

Core One Labs Inc. (OTC PINK:CLABF) has completed its acquisition of Ketamine Infusions Centers of Texas Inc. (KICT), marking its first foray into the U.S. market. This acquisition aims to establish a patient base for psychedelic-assisted psychotherapy using psilocybin, pending legalization. The transaction involves issuing 210,000 common shares and paying finder’s fees. Furthermore, Core One has been added to the Horizons Psychedelic Stock Index ETF, enhancing investor exposure. The acquisition positions Core One as a key player in addressing mental health issues exacerbated by COVID-19.

Core One Labs Inc. (CSE: COOL, OTC: CLABF) has applied for a listing on the Capital Market tier of Nasdaq, aiming to enhance investor awareness and market liquidity. The listing is contingent upon meeting several conditions, including SEC registration and Nasdaq's qualifying criteria. CEO Joel Shacker highlighted that this move aligns with the company's U.S. expansion plans and will support its capital base. However, successful listing is not guaranteed and may require share capital consolidation. Regardless, shares will continue trading on the CSE.

Core One Labs Inc. (CSE: COOL, OTC: CLABF) has filed an application for its common shares to be listed on the Capital Market tier of Nasdaq. This move aims to enhance investor awareness and liquidity for current and future shareholders. The listing depends on meeting specific criteria from Nasdaq and the SEC, including a potential consolidation of shares to meet pricing requirements. Regardless of the Nasdaq outcome, Core One plans to continue trading on the Canadian Securities Exchange. The company focuses on developing psychedelic medicines through innovative delivery systems and practices.

Core One Labs Inc. (OTC PINK: CLABF) has announced the acceptance of its Form 211 by the Financial Industry Regulatory Authority, enabling its shares to trade on the OTC Pink Market. This milestone allows U.S. investors easier access to the Company’s shares, enhancing liquidity and potentially expanding its shareholder base. Core One is focused on developing psychedelic medicines, utilizing a novel oral delivery system. The Company continues to trade on the Canadian Securities Exchange and Frankfurt Exchange under its existing symbols.

Core One Labs Inc. (OTC PINK:CLABF) has acquired Bluejay Mental Health Group Inc., effective March 11, 2021. This strategic acquisition enhances Core One's telehealth capabilities and broadens its patient network, allowing for the integration of psychedelic-assisted therapies. Bluejay has assessed over 77,000 patients and has a robust network of over 1,000 referring physicians. The acquisition is expected to facilitate product development and commercialize psychedelic treatments while leveraging Bluejay's expertise in cannabinoid therapy.

Core One Labs Inc. (OTC PINK:CLABF) announces a partnership with Ketamine Infusions Centers of Texas to explore DMT-assisted psychotherapy for anxiety and depression. Following the UK's MHRA approval for clinical trials on DMT, the company aims to capitalize on its rapid onset and short duration, similar to ketamine. The CEO emphasizes DMT's potential in treating depression. The company also plans to provide updates regarding its proposed Nasdaq listing.

Core One Labs Inc. (OTC:CLABF) announced a licensing agreement between its subsidiary, Vocan Biotechnologies Inc., and Vocan Brazil Biotechnologies Inc. for proprietary biosynthetic psilocybin technology. This agreement allows Vocan Brazil to produce and sell psilocybin products in Brazil, a market known for its progressive psychedelic laws. The licensing term is five years, with royalties based on sales, starting with a $250,000 annual fee upon market launch. The collaboration capitalizes on Brazil's healthcare system and addresses mental health issues like depression and anxiety.